Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec has entered into a research collaboration with Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm).
Subscribe to our email newsletter
Evotec has entered into multiple collaborations with top academic institutions in the USA, Germany and the UK. This collaboration with Inserm marks the initiation of the first project under Evotec's and Sanofi's Academic Bridge, which was established as a result of the multi-component strategic alliance between the companies effective 01 April 2015.
This Academic Bridge aims to accelerate the translation of promising cutting-edge science from French academic institutions into pharmaceutical product candidates. In this joint effort, Evotec scouts and incubates projects generated in France under its EVT Innovate strategy.
A year after initiating the French Academic Bridge, the first collaboration between Evotec and Prof. Gilles Favre's team from Inserm/the Université Toulouse III – Paul Sabatier/Oncopole de Toulouse has started.
The research collaboration's goal is to characterise and develop new selective modulators of RhoB functions as a promising approach to increase therapeutic options in many cancers with high unmet medical need.
RhoB is an exciting oncological target implicated in the control of cellular stress response, migration, tumour neovascularisation and progression.
Inserm Transfert chairman of the executive management board Pascale Augé said: "We happily welcome the signing of this partnership with Evotec. It will allow Prof. Favre and his team to further develop their research in the cancer field and move to the industrial development."
Evotec chief scientific officer Cord Dohrmann added: "We are excited to be part of this great research initiative that combines the best-in-class ingredients of what is needed for highly innovative and differentiated drug candidates in oncology.
"This is Evotec's first of hopefully many more academic collaborations in France. We are very proud to add Inserm to our academic partners, thereby further broadening our efforts to bridge leading academic science into industry standard drug discovery programmes."